

***Clinical Criteria* updates**

On November 19, 2021, December 13, 2021, and January 10, 2022, the Pharmacy and Therapeutics (P&T) Committee approved the following *Clinical Criteria* applicable to the medical drug benefit for Anthem Blue Cross and Blue Shield Medicaid. These policies were developed, revised, or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. For questions or additional information, use this [email](#).

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

Please note: The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.

Effective date	Document number	<i>Clinical Criteria</i> title	New or revised
September 1, 2022	*ING-CC-0205	<i>Fyarro (sirolimus albumin bound)</i>	New
September 1, 2022	*ING-CC-0206	<i>Besremi (ropeginterferon alfa-2b-njft)</i>	New
September 1, 2022	*ING-CC-0207	<i>Vyvgart (efgartigimod alfa-fcab)</i>	New
September 1, 2022	*ING-CC-0208	<i>Adbry (tralokinumab)</i>	New
September 1, 2022	*ING-CC-0209	<i>Leqvio (inclisiran)</i>	New
September 1, 2022	ING-CC-0124	<i>Keytruda (pembrolizumab)</i>	Revised
September 1, 2022	ING-CC-0079	<i>Strensiq (Asfotase Alfa)</i>	Revised
September 1, 2022	ING-CC-0102	<i>Gonadotropin releasing hormone (GNRH) Analogs for Oncologic Indications</i>	Revised
September 1, 2022	ING-CC-0168	<i>Tecartus (brexucabtagene autoleucel)</i>	Revised
September 1, 2022	ING-CC-0029	<i>Dupixent (dupilumab)</i>	Revised
September 1, 2022	*ING-CC-0004	<i>Repository Corticotropin Injection</i>	Revised
September 1, 2022	ING-CC-0072	<i>Selective Vascular Endothelial Growth Factor (VEGF) Antagonists</i>	Revised



<https://providers.anthem.com/ky>



Email is the quickest and most direct way to receive important information from Anthem Blue Cross and Blue Shield Medicaid.



To start receiving email from us (including some sent in lieu of fax or mail), submit your information using the QR code to the right or via our online form (<https://bit.ly/3lZ9oEj>).